A Neonatal Intravenous Transplant Model for Assessment of Early-Life Immune Activities Against Cancer Cells
June 26th, 2026
This protocol demonstrates temporal vein injection for intravenous delivery of pediatric cancer cells to neonatal mice, enabling precise, reproducible modeling of early-life immune responses against cancer. The method enables assessment of the impact of interventions, such as immunomodulation or therapy, when applied during the neonatal period.
We study how early life immunity influences pediatric cancer progression and whether neonatal immune responses can suppress or promote cancer progression. Current models lack precise neonatal intravenous delivery. This protocol ensures efficient delivery and consistent modeling of early life immune responses.
To begin, place freshly-prepared suspensions of luciferase-tagged leukemic cells derived from E mu-retin mice or neuroblastoma cells derived from Th-MYCN mice on ice before neonatal transplantation. Load 60 microliters of the cell suspension into a 100-microliter glass syringe. Then attach a 30-gauge needle.
Expel the suspension back into the tube to fill the dead volume of the syringe and needle. Then aspirate 20 microliters of the cell suspension containing either 1 times 10 to the power of 4 leukemic cells for BALB/c recipients or 5 times 10 to the power of 4 neuroblastoma cells for Th-MYCN recipients ensuring no air bubbles are introduced. Prepare a transilluminated stage by placing a cold light source beneath a plexiglass platform.
Next, place a sterile napkin with a central hole on the stage. Wear magnifying eyewear to visualize the injection site. Then place a small piece of modeling clay to stabilize the needle during injection.
Position the hypothermia-immobilized postnatal day one or two pup on the napkin and adjust its position until the temporal vein is clearly visible. Then insert the needle, bevel up, into the visible temporal vein, and push the plunger to slowly inject the cell suspension. Observe vascular filling to confirm successful intravenous delivery.
Apply gentle pressure to the injection site using a sterile cotton swab. Then place the pup on a warmed recovery surface at approximately 37 degrees Celsius with a towel barrier. Allow recovery until normal movement and pink coloration return.
Monitor the pup for 5 to 10 minutes after recovery, and return the pup to the dam. Rinse the syringe with PBS followed by a syringe-cleaning solution. And finally, with 70%ethanol.
Prepare the pup for bioluminescence imaging six days after the temporal vein injection. Retrieve an aliquot of filter-sterilized D-luciferin from the freezer. Using a 30-gauge needle, inject the pup with 50 microliters of D-luciferin intraperitoneally.
Next, place the anesthetized pup on a warmed imaging stage at approximately 37 degrees Celsius. 10 minutes after the injection, acquire bioluminescence and x-ray images using consistent exposure settings. Set the exposure time to 120 seconds.
Use medium binning, and set the x-ray power level to high. Intraperitoneally inject postnatal day-seven pups with murine cytomegalovirus, or MCMV, six days after temporal vein transplantation of cancer cells. Repeat the bioluminescence imaging procedure, 10 days post-viral injection, to evaluate the effect of infection-driven immune activation on tumor progression.
Then define whole body regions of interest for each mouse using bioluminescence imaging software and quantify the emitted light. Finally, export the quantified region of interest values for downstream statistical analysis. Bioluminescence imaging, combined with x-ray imaging, confirmed successful engraftment of leukemic cells and neuroblastoma cells at postnatal day seven, revealing that temporal vein injection achieved 100%procedural success.
MCMV-infected mice showed a significant reduction in leukemia burden at postnatal day 17 compared with control mice. Quantification of bioluminescent signal demonstrated a significant reduction in leukemic burden in MCMV-infected mice compared with controls at postnatal day 17. Flow cytometric quantification showed significantly fewer leukemic cells in the spleen and bone marrow of MCMV-treated mice compared with controls.
In contrast, the neuroblastoma burden at postnatal day 17 was comparable between MCMV-infected mice and control mice. This protocol enables longitudinal tracking of cancer progression and evaluation of early life immune modulation using bioluminescence imaging. The main challenge is accurate temporal vein injection within a narrow neonatal window, requiring careful technique and proper visualization.
Future studies can explore different pediatric cancers and immune stimuli, vaccines, or therapies to define mechanisms of immune-mediated cancer control in early life.
View the full transcript and gain access to thousands of scientific videos
Overview
This article presents a neonatal transplantation model combined with bioluminescent in vivo imaging to study how early-life immune modulation affects pediatric cancer progression and therapy response. The methodology enables reproducible tumor engraftment in neonatal mice and allows for the investigation of cancer-specific immune interactions during a critical developmental window.
Key Study Components
Area of Science
- Pediatric oncology
- Immunology
- In vivo imaging
Background
- Over half of pediatric cancers are initiated in utero and progress during the neonatal period.
- Neonatal immune responses differ significantly from those in older children and adults.
- Immunotherapies are emerging as treatment options for pediatric cancers.
- The influence of early-life immunity on cancer progression and therapy response is not fully understood.
Purpose of Study
- To develop a reproducible neonatal transplantation model for pediatric cancers.
- To integrate bioluminescent imaging for monitoring tumor engraftment and progression.
- To investigate the effects of early-life immune modulation on cancer outcomes.
Methods Used
- Temporal vein injection of luciferase-tagged cancer cells into 1–2-day-old syngeneic neonatal mice.
- Bioluminescent in vivo imaging to confirm tumor engraftment and monitor progression.
- Experimental immune modulation via intraperitoneal infection with murine cytomegalovirus five days post-transplantation.
- Assessment of tumor burden in models of acute lymphoblastic leukemia (ALL) and neuroblastoma (NB).
Main Results
- High procedural success and no procedure-related mortality in neonatal recipients.
- Reproducible engraftment of luciferase-tagged ALL and NB cells confirmed by imaging.
- Infection-driven immune modulation significantly reduced ALL burden but not NB burden.
- The model reveals cancer-specific differences in response to early-life immune modulation.
Conclusions
- The neonatal transplantation and imaging platform is versatile and highly reproducible.
- It enables mechanistic studies of neonatal immune responses to cancer and immunomodulation.
- The approach is adaptable to other pediatric cancers and immunotherapeutic strategies.
Frequently Asked Questions
Executive Industry Relevance
Early-life immune mechanisms play a critical role in pediatric cancer progression and therapeutic response, yet remain poorly characterized in preclinical pipelines. This neonatal intravenous transplant model enables mechanistic de-risking and target validation for immunomodulatory strategies in pediatric oncology. The platform supports predictive confidence at the intersection of immunotherapy development and early-life disease modeling, informing portfolio decisions for pediatric cancer interventions.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of neonatal immune surveillance mechanisms against cancer cells.
- Supports functional target validation for immunomodulatory interventions in early-life settings.
- Facilitates mechanistic de-risking by distinguishing cancer-specific immune responses.
- Provides a foundation for predictive confidence in pediatric immunotherapy pipelines.
Screening & Assay Development
- Delivers a reproducible in vivo system for quantitative assessment of tumor burden via bioluminescent imaging.
- Standardizes engraftment and immune modulation protocols for cross-study comparability.
- Enables scalable evaluation of immunomodulatory agents in neonatal cancer models.
- Supports reliable screening of candidate interventions targeting early-life immune pathways.
Translational & Preclinical Research
- Aligns preclinical models with disease-relevant neonatal immune contexts for pediatric oncology.
- Enables translational biomarker discovery by linking immune modulation to tumor response.
- Supports risk-adjusted advancement of immunotherapeutic strategies for pediatric indications.
- Facilitates continuity from mechanistic discovery to preclinical validation in early-life cancer research.
Pipeline & Workflow Integration
This model integrates into the discovery-to-preclinical continuum for pediatric immuno-oncology, bridging early mechanistic studies and translational evaluation.
- Discovery Biology: Provides a platform for hypothesis testing of immune-cancer interactions in neonatal hosts.
- Screening: Offers quantitative, reproducible readouts for tumor burden and immune modulation effects.
- Analytics: Enables statistical comparison of cancer-specific responses to immune interventions.
- Translational Research: Connects neonatal immune mechanisms to preclinical assessment of therapeutic strategies.
- Enterprise Reuse: Adaptable to additional pediatric malignancies and immunomodulatory approaches for broad R&D utility.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in pediatric immunotherapy development.
- Operational Value: Delivers standardized, scalable, and reproducible in vivo workflows for early-life cancer modeling.
- Strategic Value: Informs go/no-go decisions and capital allocation for pediatric oncology portfolios.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of early-life immunomodulatory candidates.
Implementation Considerations
- Requires expertise in neonatal handling, transplantation, and in vivo imaging.
- Demands access to bioluminescent imaging infrastructure and validated luciferase-tagged cell lines.
- Necessitates cross-team standardization of immune modulation and engraftment protocols.
- Adaptation to other pediatric cancer models may require optimization of cell sourcing and timing.
- Practical limitations include model specificity to neonatal immune contexts and procedural scalability.
